.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
Merck
McKinsey
Healthtrust
Julphar
Cantor Fitzgerald
Argus Health
Citi
US Army

Generated: December 12, 2017

DrugPatentWatch Database Preview

EVZIO Drug Profile

« Back to Dashboard

When do Evzio patents expire, and when can generic versions of Evzio launch?

Evzio is a drug marketed by Kaleo Inc and is included in two NDAs. There are twenty-five patents protecting this drug.

This drug has one hundred and thirty-four patent family members in fifteen countries and one supplementary protection certificate in one country.

The generic ingredient in EVZIO is naloxone hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
Drug patent expirations by year for EVZIO

Pharmacology for EVZIO

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists

Medical Subject Heading (MeSH) Categories for EVZIO

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EVZIO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,327,077Medical injector with compliance tracking and monitoring► Subscribe
9,259,539Devices, systems and methods for medicament delivery► Subscribe
8,361,026Apparatus and methods for self-administration of vaccines and other medicaments► Subscribe
9,555,191Apparatus and methods for self-administration of vaccines and other medicaments► Subscribe
9,022,980Medical injector simulation device► Subscribe
8,920,367Devices, systems and methods for medicament delivery► Subscribe
7,416,540Devices systems and methods for medicament delivery► Subscribe
8,544,645Devices, systems and methods for medicament delivery► Subscribe
9,278,177Medical injector with compliance tracking and monitoring► Subscribe
9,814,838Medicament delivery device for administration of opioid antagonists including formulations for naloxone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVZIO

Country Document Number Estimated Expiration
Poland2285360► Subscribe
United Kingdom201313756► Subscribe
New Zealand570731► Subscribe
Mexico340676► Subscribe
Japan4948422► Subscribe
Mexico2013008617► Subscribe
World Intellectual Property Organization (WIPO)2007126851► Subscribe
Canada2669616► Subscribe
United Kingdom2501213► Subscribe
United Kingdom2434548► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVZIO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Boehringer Ingelheim
Queensland Health
US Department of Justice
Express Scripts
Federal Trade Commission
Covington
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot